INTERVIEW: Dr Reddy's new chairman on why biosimilars will prevail and Russia
This article was originally published in Scrip
Dr Reddy's Laboratories (DRL) new chairman Satish Reddy's understated style and measured responses are perhaps a bit of a contrast to that of his late father and DRL's founder Dr Anji Reddy.
You may also be interested in...
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.